Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MBG453 plus hypomethylating agents in higher-risk myelodysplastic syndrome
2018-004479-11Phase 2Active
- Sponsor
- Novartis
- Start
- Apr 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in myelodysplastic syndrome (MDS) comparing MBG453 + hypomethylating agent with Placebo + hypomethylating agent (2 arms). Primary endpoint: Complete remission rate. Started Apr 2019; status: active.
02
Drugs
sabatolimab
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2018-004479-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004479-11.